| Meridian Illinois Medicaid Clinical | Lovotibeglogene Autotemcel (Lyfgenia) | 2026-01-02 |
| UHC Medicare Advantage | Hospital, Emergency, and Ambulance Services – Medicare Advantage Medical Policy | 2026-01-01 |
| UHC Medicare Advantage | Joint Procedures – Medicare Advantage Medical Policy | 2026-01-01 |
| UHC Medicare Advantage | Medicare Part B Step Therapy Programs – Medicare Advantage Medical Benefit Drug Policy | 2026-01-01 |
| UHC Medicare Advantage | Molecular Pathology/Molecular Diagnostics/Genetic Testing – Medicare Advantage Medical Policy | 2026-01-01 |
| UHC Medicare Advantage | Spine Procedures – Medicare Advantage Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Apheresis – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Autologous Cellular Therapy – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Beds and Mattresses – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Botulinum Toxins A and B – Commercial Medical Benefit Drug Policy | 2026-01-01 |